Repository logo

PNEU - Artigos publicados em revistas indexadas

Permanent URI for this collection

http://hdl.handle.net/10400.10/2420

Browse

Browsing PNEU - Artigos publicados em revistas indexadas by Author "Carreto, L"

Now showing 1 - 2 of 2
  • Interstitial Lung Disease Induced by Crizotinib in Non-Small-Cell Lung Cancer.
    Publication . Tereso, A; Carreto, L; Baptista, M; Almeida, MA
    The treatment of advanced non-small-cell lung cancer shifted with the development of molecular-targeted therapies, like the tyrosine kinase inhibitors. One example of tyrosine kinase inhibitors is crizotinib, an anaplastic lymphoma tyrosine kinase inhibitor, which targets an echinoderm microtubule-associated protein-like-4-anaplastic lymphoma kinase gene fusion. This mutation is found in only 2% to 7% of non-small-cell lung cancer cases. Although these new therapies have shown promising results, the occurrence of interstitial lung disease as a side effect could be problematic. As the diagnosis of drug-related-interstitial lung disease is difficult to make, computed tomography is an important diagnostic tool. The recognition of computed tomography manifestations of tyrosine kinase inhibitors -induced interstitial lung disease is the key for an early recognition and management of this pulmonary toxicity. We aim to raise awareness of tyrosine kinase inhibitors-induced interstitial lung disease, by reporting the first case of a Portuguese patient treated with crizotinib for non-small-cell lung cancer who developed drug-induced interstitial lung disease.
    2019Journal article Open access Show more
  • Utility of routine screening for alpha-1 antitrypsin deficiency in patients with bronchiectasis
    Publication . Carreto, L; Morrison, M; Donovan, J; Finch, S; Tan, GL; Fardon, T, et al.
    Alpha-1 antitrypsin deficiency (AATD) is a cause of bronchiectasis. Guidelines for bronchiectasis from the British Thoracic Society do not recommend to routinely test patients for AATD. In contrast, guidelines for AATD recommend routine screening. This contradiction, in part, results from the lack of data from large studies performing comprehensive screening. We screened 1600 patients with bronchiectasis at two centres in the UK from 2012 to 2016. In total, only eight individuals with AATD were identified representing 0.5% of the overall population. We conclude that routine screening for AATD in bronchiectasis in the UK has a low rate of detection. Further studies are required in different geographical regions, which may have a higher prevalence of AATD.
    2020Journal article Open access Show more